Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.7468
+0.04666.66%
Post-market: 0.6300-0.1168-15.64%17:20 EDT
Volume:4.49M
Turnover:3.26M
Market Cap:167.81M
PE:-1.54
High:0.7624
Open:0.6897
Low:0.6874
Close:0.7002
Loading ...

Press Release: Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Dow Jones
·
37 mins ago

Sangamo Therapeutics Delays Q1 2025 Earnings Call to Later Time on May 12

Reuters
·
1 hour ago

Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Dow Jones
·
07 May

Sangamo Therapeutics: St-920 Study Pivotal Data Readout Expected by End of Q2 2025

THOMSON REUTERS
·
06 May

Sangamo Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
05 May

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Business Wire
·
29 Apr

US Stocks Likely To Open Lower After The Worst Selloff Since 2020: Tariff Announcement Was '100% Smoot Hawley Disguised As Thoughtful Policy,' Says Expert

Benzinga
·
04 Apr

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Benzinga
·
04 Apr

Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones
·
04 Apr

BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

Reuters
·
04 Apr

Shares of Sangamo Therapeutics Rally on Licensing Deal With Eli Lilly

Dow Jones
·
04 Apr

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours

MT Newswires Live
·
04 Apr

Sangamo Therapeutics Enters Capsid License Agreement With Lilly

Dow Jones
·
04 Apr

Sangamo: Agreement Grants Lilly Rights to Employ Co's Novel Proprietary Capsid, Stac-Bbb, for up to 5 Potential Disease Targets

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Eligible to Earn up to $1.4 Bln in Additional Licensed Target Fees and Milestone Payments

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Inc: Sangamo to Receive an $18 Mln Upfront License Fee

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

THOMSON REUTERS
·
04 Apr

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Business Wire
·
04 Apr

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5

MT Newswires Live
·
19 Mar